Evidence map›Paper›PMID 40962326›Full record

ArticleBMB reports2026

Lefty2 prevents RANKL-induced bone loss by inhibiting osteoclast differentiation.

Jung Ha Kim, Kabsun Kim, Inyoung Kim, Semun Seong, Nacksung Kim

Abstract read
In one paragraph

Article in BMB reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jung Ha KimDepartment of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Korea.
Kabsun KimDepartment of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Korea.
Inyoung KimDepartment of Pharmacology, Chonnam National University Medical School, Gwangju 61469; Hard-Tissue Biointerface Research Center, School of Dentistry, Chonnam National University, Gwangju 61186, Korea.
Semun SeongDepartment of Pharmacology, Chonnam National University Medical School, Gwangju 61469; Hard-Tissue Biointerface Research Center, School of Dentistry, Chonnam National University, Gwangju 61186, Korea.
Nacksung KimDepartment of Pharmacology, Chonnam National University Medical School, Gwangju 61469; Hard-Tissue Biointerface Research Center, School of Dentistry, Chonnam National University, Gwangju 61186, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Left-right determination factor 2 (Lefty2) is a transforming growth factor-β (TGF-β) receptor ligand that is critical for organ asymmetry and cell proliferation. More broadly, the TGF-β superfamily plays indispensable roles in development and gene regulation, and TGF-β family ligands are instrumental in osteoclast differentiation and bone resorption. In the present study, we show that Lefty2 dramatically inhibits receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclast differentiation. We found that this effect was associated with inhibition of early intracellular signaling pathways activated by RANKL, which are important for osteoclast differentiation. Furthermore, administration of exogenous Lefty2 prevented RANKLinduced bone loss in mice. Interestingly, transgenic mice expressing Lefty2 controlled by the Mx-1 promoter did not show a distinct bone phenotype, even though transgenic mouse-derived bone marrow macrophages exhibited reduced osteoclast formation compared to controls in vitro. [BMB Reports 2026; 59(1): 78-83].

Indexed as

Bone ResorptionOsteoclastsRANK LigandAnimalsCell DifferentiationMiceMice, Inbred C57BLMice, TransgenicOsteogenesisSignal TransductionRANK Ligand

Identifiers

PMID40962326
PMCPMC12867179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.